AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System
AngioDynamics (NASDAQ: ANGO) has announced a virtual investor event scheduled for January 8, 2025, at 9:30am ET, following their Fiscal 2025 Second Quarter Financial Results Conference Call. The 60-minute event will showcase the company's NanoKnife™ System, featuring their proprietary irreversible electroporation (IRE) technology.
The presentation will focus on how the NanoKnife System is positioned to become the standard, function-preserving treatment for men with prostate tumors. Leaders from the company's Oncology division will discuss the system's unique mechanism of action, patient care impact, physician and patient advocacy group collaborations, and its market opportunity and commercialization strategy.
AngioDynamics, a medical technology company, specializes in restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving patient quality of life.
AngioDynamics (NASDAQ: ANGO) ha annunciato un evento virtuale per investitori programmato per l'8 gennaio 2025 alle 9:30 ET, in seguito alla conferenza sui risultati finanziari del secondo trimestre fiscale 2025. L'evento della durata di 60 minuti presenterà il Sistema NanoKnife™ dell'azienda, che ha come fulcro la propria tecnologia proprietaria di elettroporazione irreversibile (IRE).
La presentazione si concentrerà su come il Sistema NanoKnife sia posizionato per diventare il trattamento standard che preserva la funzione per gli uomini con tumori alla prostata. I leader della divisione Oncologia dell'azienda discuteranno il meccanismo d'azione unico del sistema, l'impatto sulla cura dei pazienti, le collaborazioni con i gruppi di advocacy per medici e pazienti, così come le opportunità di mercato e la strategia di commercializzazione.
AngioDynamics, un'azienda di tecnologia medica, è specializzata nel ripristino del flusso sanguigno sano nel sistema vascolare del corpo, nell'espansione delle opzioni di trattamento per il cancro e nel miglioramento della qualità della vita dei pazienti.
AngioDynamics (NASDAQ: ANGO) ha anunciado un evento virtual para inversores programado para el 8 de enero de 2025 a las 9:30 am ET, tras su conferencia sobre los resultados financieros del segundo trimestre fiscal de 2025. El evento de 60 minutos presentará el Sistema NanoKnife™ de la empresa, que destaca su tecnología propietaria de electroporación irreversible (IRE).
La presentación se centrará en cómo el Sistema NanoKnife está posicionado para convertirse en el tratamiento estándar que preserva la función para hombres con tumores de próstata. Los líderes de la división de Oncología de la empresa discutirán el mecanismo de acción único del sistema, el impacto en la atención al paciente, las colaboraciones con grupos de defensa de médicos y pacientes, así como las oportunidades de mercado y la estrategia de comercialización.
AngioDynamics, una empresa de tecnología médica, se especializa en restaurar el flujo sanguíneo saludable en el sistema vascular del cuerpo, expandir las opciones de tratamiento del cáncer y mejorar la calidad de vida de los pacientes.
AngioDynamics (NASDAQ: ANGO)는 2025년 1월 8일 오전 9시 30분 ET에 예정된 가상 투자자 이벤트를 발표했습니다. 이 이벤트는 2025 회계연도 2분기 재무 결과 컨퍼런스 콜 이후에 열리며, 60분 동안 NanoKnife™ 시스템을 선보일 것입니다. 이 시스템은 회사의 독점적인 비가역적 전기영동(IRE) 기술을 특징으로 합니다.
프레젠테이션은 NanoKnife 시스템이 전립선 종양을 가진 남성에게 기능을 보존하는 표준 치료법으로 자리잡는 방법에 초점을 맞출 것입니다. 회사의 종양학 부서 리더들이 시스템의 독특한 작용 메커니즘, 환자 관리의 영향, 의사 및 환자 옹호 단체와의 협업, 그리고 시장 기회 및 상업화 전략에 대해 논의할 것입니다.
AngioDynamics는 신체의 혈관 시스템에서 건강한 혈류를 복원하고, 암 치료 옵션을 확장하며, 환자의 삶의 질을 개선하는 데 전문화된 의료 기술 기업입니다.
AngioDynamics (NASDAQ: ANGO) a annoncé un événement virtuel pour les investisseurs prévu pour le 8 janvier 2025 à 9h30 ET, suite à la conférence téléphonique sur les résultats financiers de son deuxième trimestre fiscal 2025. Cet événement de 60 minutes présentera le Système NanoKnife™ de l'entreprise, qui met en avant sa technologie propriétaire d'électroporation irréversible (IRE).
La présentation se concentrera sur la manière dont le Système NanoKnife est positionné pour devenir le traitement standard préservant la fonction pour les hommes atteints de tumeurs de la prostate. Des responsables de la division Oncologie de l'entreprise discuteront du mécanisme d'action unique du système, de l'impact sur les soins aux patients, des collaborations avec des groupes de défense des médecins et des patients, ainsi que des opportunités de marché et de la stratégie de commercialisation.
AngioDynamics, une entreprise de technologie médicale, se spécialise dans la restauration d'un flux sanguin sain dans le système vasculaire du corps, l'extension des options de traitement du cancer et l'amélioration de la qualité de vie des patients.
AngioDynamics (NASDAQ: ANGO) hat eine virtuelle Investorenveranstaltung angekündigt, die für den 8. Januar 2025 um 9:30 Uhr ET geplant ist, im Anschluss an die Telefonkonferenz zu den finanziellen Ergebnissen des zweiten Quartals des Geschäftsjahres 2025. Die 60-minütige Veranstaltung wird das NanoKnife™-System des Unternehmens vorstellen, das auf dessen proprietärer irreversibler Elektroporation (IRE) Technologie basiert.
Die Präsentation wird sich darauf konzentrieren, wie das NanoKnife-System als der Standard zum funktionsbewahrenden Behandlung von Männern mit Prostatatumoren positioniert ist. Führungskräfte aus der Onkologie-Abteilung des Unternehmens werden den einzigartigen Wirkmechanismus des Systems, die Auswirkungen auf die Patientenversorgung, die Zusammenarbeit mit Medizinern und Patientenvertretungsgruppen sowie die Marktchancen und die Kommerzialisierungsstrategie erörtern.
AngioDynamics, ein Unternehmen für Medizintechnologie, hat sich auf die Wiederherstellung eines gesunden Blutflusses im vaskulären System des Körpers, die Erweiterung der Möglichkeiten zur Krebsbehandlung und die Verbesserung der Lebensqualität der Patienten spezialisiert.
- None.
- None.
Virtual NanoKnife System Event
Date: Wednesday, January 8, 2025
Time: 9:30am ET
Duration: 60 minutes
Webcast Registration Link: https://viavid.webcasts.com/starthere.jsp?ei=1703585&tp_key=2c4874e6e2
Event Overview
Attendees will gain insights into the NanoKnife System’s proprietary irreversible electroporation (IRE) technology and how it is poised to become the standard, function-preserving treatment for men with prostate tumors.
The event will feature leaders from the Company’s Oncology division discussing the NanoKnife System’s unique mechanism of action and impact on patient care, collaboration with physicians and patient advocacy groups, as well as its market opportunity and commercialization roadmap.
About the NanoKnife System
The NanoKnife System utilizes Irreversible Electroporation technology to effectively destroy targeted cells without the use of thermal energy by delivering high-voltage pulses, creating permanent nanopores within the cell membrane. This stimulus induces an apoptotic-like cellular death in the targeted tissue, resulting in a complete ablation of the targeted tissue.1 Visit nanoknife.com for full product information.
European Union: The NanoKnife System is indicated for the ablation of prostate tissue in patients with intermediate risk prostate cancer.
About AngioDynamics, Inc.
AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.
The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.
1 Lee EW, Thai S, Kee ST. Irreversible electroporation: a novel image-guided cancer therapy. Gut Liver. 2010;4 Suppl 1(Suppl 1):S99-S104. doi:10.5009/gnl.2010.4.S1.S99
View source version on businesswire.com: https://www.businesswire.com/news/home/20250106846681/en/
Investors:
AngioDynamics, Inc.
Stephen Trowbridge, Executive Vice President & CFO
(518) 795-1408
strowbridge@angiodynamics.com
Media:
Saleem Cheeks
Vice President, Communications
518-795-1174
scheeks@angiodynamics.com
Source: AngioDynamics, Inc.
FAQ
When is AngioDynamics (ANGO) hosting its NanoKnife System virtual investor event?
What is the primary application of ANGO's NanoKnife System?
How long will ANGO's NanoKnife System virtual event last?
What topics will be covered in ANGO's NanoKnife System presentation?
How can investors attend ANGO's NanoKnife System virtual event?
